HOME >> BIOLOGY >> NEWS
Algal contact as a trigger for coral disease

Infectious disease epidemics are causing widespread and alarming declines in reef-building coral species, the foundation blocks of coral reef ecosystems. The emergence of these diseases has occurred simultaneously with large increases in the abundance of seaweeds, called macroalgae.

Macroalgae frequently interact with corals, usually by overgrowing them from their edges. In the October issue of Ecology Letters, Nugues, Smith, van Hooidonk, Seabra and Bak demonstrate a sinister aspect of this competition. One of the most common macroalgae, Halimeda opuntia, is shown to trigger a particularly virulent disease known as white plague type II.

In the Caribbean, a large number of coral colonies on which this alga was transplanted developed white plague whereas unexposed colonies did not. In addition, the plant was found to be a reservoir for the marine bacterium Aurantimonas coralicida, causative agent of the disease. The spread of macroalgae on coral reefs may account for the elevated incidence of coral diseases over past decades. Moreover, measures to reduce seaweed abundance may be essential if significant coral populations are to survive on coral reefs.


'"/>

Contact: Kate Stinchcombe
kate.stinchcombe@oxon.blackwellpublishing.com
Blackwell Publishing Ltd.
17-Sep-2004


Page: 1

Related biology news :

1. Algal food quality, not quantity, critical factor in healthy lake ecosystems
2. Nanoscale contact optimizes adhesion
3. Chimpanzees with little or no human contact found in remote African rainforest
4. New antibacterial coating may prolong contact lens life
5. Adhesive interactions in contact dermatitis
6. New contact-lens materials will revolutionize the industry, UT Southwestern researchers report
7. NU professor works toward a permanently germ-free surface: Polymer glass coating capable of killing airborne bacteria on contact
8. Study suggests cell-cycle triggers might be cancer drug targets
9. Good bacteria trigger proteins to protect the gut
10. Inflammations trigger finger
11. Sick Kids researchers look at viral triggers for multiple sclerosis in children

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Algal contact trigger for coral disease

(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
(Date:12/3/2014)... , Dec. 2, 2014 As part of ... Inception Technologies is pleased to announce the release of ... customers to collect the workforce data that they need. ... have been left by existing readers. Many such devices ... connectivity and modern technology. Older models force users to ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
(Date:12/19/2014)... (PRWEB) December 18, 2014 LayerBio is ... ophthalmology and wound care. The National Eye Institute (NEI) ... LayerBio a Phase I SBIR grant to develop a ... are the most common cause of vision loss in ... blindness worldwide. According to Dr. Ken Mandell, LayerBio’s Founder ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... Dec. 18, 2014 Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced the results of its ... "This was a transformational year in Relmada,s history and ... our company," said Sergio Traversa , chief executive ... executed on key financial, human resource and clinical development ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: